Search Within

Niloufer Khan

Formats
  1. Meeting Abstract (28)
  2. Journal Article (15)
  3. Editorial (2)
  4. Correspondence (1)
  5. Miscellaneous (1)
  6. Review (1)
Groups
  1. Hematologic Malignancies, Division of (48)
  2. Survivorship Research (48)
  3. Department of Medicine (44)
  4. Center for Hematologic Malignancies (41)
  5. Lymphoma (34)
  6. Population Sciences Research Program (32)

More Groups

People
  1. Steven Horwitz (28)
  2. Alison Moskowitz (26)
  3. Andrew Zelenetz (17)
  4. Matthew Matasar (17)
  5. Anita Kumar (15)
  6. Ariela Noy (15)

More People

Years
  1. 2023 (5)
  2. 2022 (12)
  3. 2021 (13)
  4. 2020 (4)
  5. 2019 (7)
  6. 2018 (6)

More Years

Publications
  1. Blood (20)
  2. Journal of Clinical Oncology (4)
  3. Hematological Oncology (3)
  4. Leukemia and Lymphoma (3)
  5. Biology of Blood and Marrow Transplantation (2)
  6. Blood Advances (2)

More Publications

Publishers
  1. American Society of Hematology (22)
  2. Elsevier Inc. (5)
  3. American Society of Clinical Oncology (4)
  4. Taylor & Francis Group (4)
  5. Wiley Blackwell (3)
  6. Springer (1)

More Publishers

Results (48)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience
    Meeting Abstract

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The potential for technology to aid quantitative assessment in cutaneous T cell lymphoma
    Correspondence

    Gu, L.; Oh, Y.; Smith, M. P.; Kurtansky, N. R.; Horwitz, S.; Kahn, N.; Moskowitz, A.; Noor, S. J.; Myskowski, P.; Rotemberg, V.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Pilot trial of homebound hematopoietic cell transplantation
    Journal Article

    Landau, H. J.; Orlando, E.; Rodriguez, E. S.; Applebaum, A.; Mitchell, H. R.; Peled, J. U.; Khan, N.; Funnell, T.; Chung, D.; Scordo, M.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Top ten tips palliative care clinicians should know about caring for patients with cutaneous T cell lymphoma
    Editorial

    Salant, J. A.; Khan, N.; Nelson, J. E.; Norton-Westbrook, M.; Desai, A. V.
    Journal of Palliative Medicine (2022)

    Fulltext@MSK | Save
  • Current treatment of peripheral T-cell lymphoma
    Review

    Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Lewis, N.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M.
    Oncology (Norwalk) (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save